悦康药业
(688658)
| 流通市值：113.40亿 | | | 总市值：113.40亿 |
| 流通股本：4.50亿 | | | 总股本：4.50亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,167,382,036.87 | 577,383,322.42 | 3,780,875,989.99 | 2,991,795,632.65 |
| 营业收入 | 1,167,382,036.87 | 577,383,322.42 | 3,780,875,989.99 | 2,991,795,632.65 |
| 二、营业总成本 | 1,269,538,108.89 | 629,257,575.77 | 3,563,397,787 | 2,730,072,277.72 |
| 营业成本 | 588,714,164.95 | 318,826,772.77 | 1,595,483,109.87 | 1,185,398,827.66 |
| 税金及附加 | 18,639,263.21 | 8,856,455.3 | 46,897,915.11 | 38,401,152.55 |
| 销售费用 | 318,386,243.57 | 130,662,783.63 | 1,301,868,005.85 | 1,077,257,545.89 |
| 管理费用 | 133,280,166.95 | 70,124,118.71 | 239,868,373.07 | 164,333,471.07 |
| 研发费用 | 203,049,828.36 | 97,173,001.2 | 374,306,998.74 | 261,146,138.06 |
| 财务费用 | 7,468,441.85 | 3,614,444.16 | 4,973,384.36 | 3,535,142.49 |
| 其中:利息费用 | 11,337,095.89 | 5,749,418.81 | 22,395,514.29 | 17,187,238.11 |
| 其中:利息收入 | -4,033,697.21 | 2,206,721.81 | 17,618,186.88 | 14,914,712.09 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 37,997.51 | - | 2,344,894.08 | - |
| 加:投资收益 | 1,385,511.85 | 593,445.97 | 442,391.76 | - |
| 资产处置收益 | - | - | -383,536.49 | 29,443.79 |
| 资产减值损失(新) | -18,583,861.35 | -14,511,783.51 | -100,545,979.23 | -34,174,805.44 |
| 信用减值损失(新) | -746,336.36 | 1,226,553.19 | 6,264,713.36 | 4,478,983.3 |
| 其他收益 | 13,375,322.35 | 6,113,637.63 | 33,462,220.9 | 22,915,446.94 |
| 四、营业利润 | -106,687,438.02 | -58,452,400.07 | 159,062,907.37 | 254,972,423.52 |
| 加:营业外收入 | 645,207.8 | 371,335.5 | 4,026,558.96 | 2,166,091.78 |
| 减:营业外支出 | 1,212,289.93 | 948,564.05 | 10,731,858.98 | 8,868,118.92 |
| 五、利润总额 | -107,254,520.15 | -59,029,628.62 | 152,357,607.35 | 248,270,396.38 |
| 减:所得税费用 | -5,074,369.01 | -9,531,384.48 | 31,110,723.46 | 40,069,856.69 |
| 六、净利润 | -102,180,151.14 | -49,498,244.14 | 121,246,883.89 | 208,200,539.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -102,180,151.14 | -49,498,244.14 | 121,246,883.89 | 208,200,539.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -98,829,145.21 | -49,271,134.83 | 123,717,028.86 | 209,725,063.28 |
| 少数股东损益 | -3,351,005.93 | -227,109.31 | -2,470,144.97 | -1,524,523.59 |
| 扣除非经常损益后的净利润 | -108,465,246.01 | -53,471,806.21 | 110,758,662.86 | 201,930,530.98 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.22 | -0.11 | 0.28 | 0.47 |
| (二)稀释每股收益 | -0.22 | -0.11 | 0.28 | 0.47 |
| 九、综合收益总额 | -102,180,151.14 | -49,498,244.14 | 121,246,883.89 | 208,200,539.69 |
| 归属于母公司股东的综合收益总额 | -98,829,145.21 | -49,271,134.83 | 123,717,028.86 | 209,725,063.28 |
| 归属于少数股东的综合收益总额 | -3,351,005.93 | -227,109.31 | -2,470,144.97 | -1,524,523.59 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-03-15 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |